Search hospitals
>
Connecticut
>
Hartford
Smilow Cancer Hospital Care Center at Saint Francis
Claim this profile
Hartford, Connecticut 06105
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Ovarian Cancer
Conducts research for Fallopian Tube Cancer
300 reported clinical trials
44 medical researchers
Summary
Smilow Cancer Hospital Care Center at Saint Francis is a medical facility located in Hartford, Connecticut. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Ovarian Cancer, Fallopian Tube Cancer and other specialties. Smilow Cancer Hospital Care Center at Saint Francis is involved with conducting 300 clinical trials across 411 conditions. There are 44 research doctors associated with this hospital, such as Farzana Pashankar, Alessandro Santin, Amer M. Zeidan, and Joseph W. Kim, MD.
Area of expertise
Breast Cancer
Smilow Cancer Hospital Care Center at Saint Francis has run 62 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Smilow Cancer Hospital Care Center at Saint Francis has run 48 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Farzana Pashankar
Yale University
8 years of reported clinical research
Alessandro Santin
Smilow Cancer Hospital at Yale New Haven
5 years of reported clinical research
Amer M. Zeidan
Yale Cancer Center
4 years of reported clinical research
Joseph W. Kim, MD
Yale University
9 years of reported clinical research
Clinical Trials running at Smilow Cancer Hospital Care Center at Saint Francis
Lung Cancer
Breast Cancer
Breast cancer
Bladder Cancer
Multiple Myeloma
Pancreatic Cancer
Non-Small Cell Lung Cancer
Cancer
Esophageal cancer
Uterine Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting
2 awards
Phase 3
28 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Smilow Cancer Hospital Care Center at Saint Francis?
Smilow Cancer Hospital Care Center at Saint Francis is a medical facility located in Hartford, Connecticut. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Ovarian Cancer, Fallopian Tube Cancer and other specialties. Smilow Cancer Hospital Care Center at Saint Francis is involved with conducting 300 clinical trials across 411 conditions. There are 44 research doctors associated with this hospital, such as Farzana Pashankar, Alessandro Santin, Amer M. Zeidan, and Joseph W. Kim, MD.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.